Glycotope GmbH, a glycobiology company, will present recent advances with its GlycoExpress technology of novel human cell lines during the upcoming BIO-Europe in Munich.
With two of its glycooptimized antibodies produced by GlycoExpress and already undergoing clinical trials, four European regulatory authorities approved GlycoExpress for production of biotherapeutics. This strongly validates this innovative technology for future development and production of therapeutic proteins.The preclinically observed advantages of glycooptimized biotherapeutics are expected to result in a clear clinical superiority. All glycooptimized products are produced in Glycotope´s own GMP facility in Heidelberg (Glycotope Biotechnology GmbH).
GlycoExpress is based on a tool box of glycoengineered human cell lines for glycooptimization and high yield production of glycooptimized biotherapeutics, such as antibodies. The antibody’s fully human glycosylation is optimized to yield a largely improved anti-tumor ADCC activity, bioavailability and contains no non-human immunogenic carbohydrate structures and facilitates treatment of a highly increased number of patients. Glycooptimization with GlycoExpress is not limited to antibodies but suitable for the majority of therapeutically relevant proteins. The technology platform is available for co-operation partners via service & license agreements.
Glycotope GmbH
